INTRODUCTION

81
At exercise start, the characteristics of the heart rate (HR) kinetics under vagal 82 blockade (12) suggested that sudden withdrawal of vagal tone may occur. This 83 hypothesis may explain the concomitant sudden increase of cardiac output (13, 25) . 84
Recently, vagal withdrawal was called upon also to explain the early changes in 85 baroreflex sensitivity upon exercise start (4). If this is so, we should expect that the 86 amplitude of the rapid HR and cardiac output responses would be greater, the 87 stronger is the vagal modulation of heart activity at rest. 88
The experimental evidence, however, is not conclusive under this respect, and 89 several data seem to contradict the vagal withdrawal hypothesis. For instance, 90 although we know that resting vagal activation is greater in supine than in upright 91 position (35, 47, 49) , the amplitude of the rapid cardiac output response at exercise 92 onset was found to be smaller in supine than in upright posture (27; 55) . On the other 93 hand, vagal activity is reduced and sympathetic activation is increased in acute 94 hypoxia as compared to normoxia (5;18, 23, 57, 58) : in spite of this, even in hypoxia 95 HR determined a large fraction of a significant cardiac output response (26). These 96 data represent a serious challenge to the vagal withdrawal hypothesis at exercise 97 onset. 98
The vagal withdrawal hypothesis at exercise onset may also be tested by 99
investigating the neural modulation of the heartbeat under pharmacological blockade 100 of either the vagal or the sympathetic or both branches of the ANS (2, 6, 15, 17, 21, 101 they did not find differences under vagal blockade with glycopyrrolate; moreover, 108 esmolol administration provided similar results as placebo. The interpretation of their 109 results was undermined by the type of drug used and their study was limited by the 110 fact that they did not analyse blood pressure variability, another important indirect 111 feature of sympathetic modulation of the cardiovascular system. Polanczyk et al. (42) 112 showed that atropine and propranolol administration did not vary the spectrum 113 components of HRV, contrary to their expectations. 114
If the vagal withdrawal hypothesis was correct, we should predict that, when 115 comparing rest and exercise: i) no differences in PTOT, LF and HF under full vagal 116 blockade would be found; ii) a drastic fall in PTOT, LF and HF under selective 1-117 sympathetic blockade would occur; iii) no differences in PTOT, LF and HF under 118 simultaneous blockade of the two branches of the ANS would appear. Moreover, we 119 expected that arterial blood pressure variability would not follow the same pattern of 120 response as HRV, because the former reflects more the peripheral sympathetic 121 vascular modulation than the central cardiac modulation. 122
These predictions were tested in the present study, the aim of which was to 123 investigate the effects of vagal blockade, of selective 1-sympathetic blockade and of 124 simultaneous blockade of both branches of the ANS, at rest and during exercise, on 125
HRV and blood pressure variability. 126 weighed 78.9 ± 6.1 kg. Exclusion criteria were: presence of history of 134 cardiopulmonary disease and regular use of drugs at the time of the study. 135
Participants were instructed to avoid caffeine consumption 24 hours before the visit 136 and to refrain from performing strenuous exercise the day before testing. 137
All participants were preliminarily informed on the design and risks 138 associated with the experiments and they signed a written informed consent. The 139 study was conducted in accordance with the Declaration of Helsinki, and the protocol 140 was approved by the local institutional ethical committee. 141
142
Protocol and measurements 143
The experiments were carried out in the Clinical Physiology Laboratory of the 144 University of Geneva, Switzerland. The volunteers reported to the laboratory on four 145 different days, with at least a 48-hour recovery between visits. Experiments were 146 performed in supine posture, in order to reduce potential mechanical effects related 147 to the remarkable sudden increase in venous return at exercise start upright. After 148 instrumentation, a 20-gauge catheter was placed in the antecubital vein of the right 149 arm to administer drugs. A unique 5-min monitoring at rest preceded a series of three 150 5-min constant-load leg exercises, on cycle ergometer, at 80 watts, to avoid lactate 151 threshold. Between repetitions a 5-min recovery was administered. 152
For the entire duration of the protocol, we obtained continuous recordings of 153 the electrocardiogram (Elmed ETM 2000, Heiligenhaus, Germany), and the arterial 154 pulse pressure profiles, obtained at a fingertip of the left arm by means of a non-155 invasive cuff pressure recorder (Portapres, FMS, Amsterdam, The Netherlands). 156
The R-R interval (RR) and its reciprocal, HR, were computed beat-by-beat. 7 obtained from each pulse pressure profile, using the Beatscope® software package 159 (FMS, Amsterdam, The Netherlands). Beat-by-beat mean arterial pressure (MAP) 160 was computed as the integral mean of each pressure profile, using the same 161 software package. Breathing frequency was also calculated from the 162 electrocardiogram plot. 
Drug administration 174
Parasympathetic blockade was achieved by administering atropine in a 175 single 0.04 mg/kg dose (mean 3.06 ± 0.23 mg, range 2.7 -3.4 mg), which was used 176 in previous studies to attain full vagal blockade (14, 17, 31, 59) . The half-life of a 177 single atropine dose is 180 minutes (52) so that, blockade was maintained during the 178 entire duration of each experiment. 179
The 1-adrenergic blockade was attained by using metoprolol tartrate 180 (Loprésor, Novartis, Switzerland). After an initial bolus of 15 mg, metoprolol tartrate 181 was continuously infused in an antecubital vein at a rate of 45 mg per hour, by 182 means of an infusion pump. The efficacy of adrenergic blockade along time was 183 evaluated on a separate session, by analysing the heart rate response following 184 isoprenaline injection, as previously described (14). The correct metoprolol 185 maintenance dose was identified as the dose ensuring an 80% reduction of the HR 186 response to isoprenaline for the entire protocol duration. 187
For the experiments with double, simultaneous sympathetic and 188 parasympathetic blockade, the same atropine and metoprolol dose and 189 administration procedure described here above were applied. The spontaneous baroreflex sensitivity (BRS, expressed in ms mmHg -1 ) was 206 estimated from SAP and RR by means of the sequence method (3). Sequences of at 207 least three heartbeats, corresponding to an increase or decrease in SAP and 208 identifying a consensual change in RR interval, were selected. Linear regression 209 analysis was applied on these sequences and the calculated slope was retained. 210 participant in each condition. Only sequences showing a coefficient of determination 212 of at least 0.85 were analysed. 213 Spectral analysis and BRS were performed on Matlab® environment as previously 214 described (41) with any investigated pharmacological treatment, although with double blockade, 240 DAP tended to be higher than in control and was significantly higher than under 241 metoprolol. MAP was 74.0±8.6 mmHg in control and did not differ in the three 242 investigated pharmacological conditions, except that it was higher under double 243 blockade than with metoprolol. Breathing frequency was 0.23±0.06 Hz in control and 244 did not change in the three conditions. At exercise, in control condition, SAP was 245 138.5±17.5 and DAP was 60.9±7.5 mmHg. With respect to control, SAP was 246 significantly lower under the three pharmacological conditions. No differences were 247 observed for DAP. MAP was 86.8±9.9 mmHg in control and did not vary significantly 248 among conditions. With respect to the corresponding values at rest, MAP during 249 exercise was higher only in control. Breathing frequency was 0.42±0.07 Hz in control 250 and did not change in the three other conditions. 251
HRV data are shown in Table 2 . Examples of HRV spectra are shown in 252 differences between atropine and double blockade were found. The same was the 256 case at exercise, although the difference were much smaller than at rest, because, 257 when moving from rest to exercise, PTOT was drastically reduced in control and 258 under metoprolol. No differences for LF and HF powers between sympathetic 259 blockade and control, or between atropine and double blockade, were observed. 260
At rest, the LF/HF ratio at rest was unaffected by drug treatment, the only 261 significant difference being between atropine and double blockade. The same was 262 the case for LFnu. No differences were observed concerning HFnu. At exercise, the 263 was lower under double blockade than in control and in the other pharmacological 265 conditions. The same was the case for LFnu. Coherently, HFnu was higher in double 266 blockade than in any other condition. 267
All data concerning spontaneous SAP and DAP variability are shown in Table  268 3. At rest, concerning SAP, no differences among conditions were observed for P TOT . 269
Concerning the LF power, no differences between sympathetic blockade and control 270 were found, but it was lower under atropine and double blockade than in control and 271 sympathetic blockade. The HF power in atropine and double blockade was lower 272 than in control and under metoprolol, although for the latter the level of significance 273 was not attained. During exercise, P TOT was lower in all three investigated 274 pharmacological conditions than in control, but no differences among conditions were 275 observed for both the LF and the HF powers. In control and under atropine, the LF 276 power was higher at exercise than at rest. The LF/HF ratio was unchanged in all 277
conditions. 278
At rest, concerning DAP, no changes in P TOT were found in any 279 pharmacological condition with respect to control. The HF power did not vary among 280 conditions, while the LF power was lower in atropine and double blockade than in 281 control. The LF/HF ratio was lower in all conditions than in control. During exercise, 282 there were no significant differences among conditions or with respect to the same 283 condition at rest. 284
The BRS values at rest and exercise are shown in Figure 2 The analysis of spontaneous heart rate variability at rest showed that: 1. 294 atropine administration drastically reduced PTOT, due to the fall of both LF and HF 295 powers, with respect to control; 2. simultaneous double blockade with atropine and 296 metoprolol provided the same results as atropine administration only; 3. metoprolol 297 administration had no effects on heart rate variability. 298
When moving from rest to exercise, our results showed that: 1. no differences 299 in PTOT, LF and HF appeared under atropine and under simultaneous atropine and 300 metoprolol administration with respect to rest; 2. PTOT, and the LF and HF powers, 301
were decreased by the same extent under metoprolol as in control. However, during 302 exercise, PTOT, and the LF and HF powers were lower under atropine and double 303 blockade than in control or with metoprolol. 304
These results are in line with the predictions made, and thus do not allow 305 refutation of the vagal withdrawal hypothesis, but rather reinforce it. Although, taken 306 separately, similar consistent results can be found in the previous literature (2, 6, 8, 307 10, 11, 15, 17, 21, 24, 29, 32, 33, 35, 43, 44) , this is the first time that a complete 308 picture of the role of the autonomic nervous system in determining heart rate 309 variability in rest and exercise was obtained. 310 rest with beta-blockade (11, 14, 15, 19) . In supine posture, the predominance of 319 vagal modulation of HR (20, 35) may explain the lack of HR changes with metoprolol. 320
Concerning HRV, metoprolol failed in changing PTOT, LF and HF at rest, 321 indicating that a selective blockade of cardiac -adrenergic receptors has no effects 322 on spontaneous HR oscillations. This suggests that the sympathetic outflow to the 323 heart may not be the main determinant of HRV, although the PTOT values under 324 double blockade appear lower (just a tendency) than under atropine. These results 325 for PTOT, although in agreement with those of some previous studies (15, 53) , are in 326 contrast with those by Cogliati et al. (11) , who showed an increase in PTOT under 327 atenolol, supporting the idea that the pattern was mostly due to an increase in the HF 328 peak. This finding suggested stronger cardio-respiratory coupling under atenolol than 329 in control. Comparable results were obtained by others (40) using propranolol. 330
Spontaneous HR oscillations were almost suppressed after atropine 331 administration, as previously found (8, 15, 21, 29, 32, 33, 53) , supporting the notion 332 that parasympathetic outflow to the heart is the major determinant of HRV in resting 333 humans. This was so also under simultaneous sympathetic and vagal blockade, 334
indicating that suppression of the parasympathetic modulation of the heartbeat was 335 the most important determinant of the present results. Breathing frequency did not 336 change in the three conditions, being obviously higher at exercise than at rest. This 337 implies that changes in HF power were not due to any change in breathing 338
frequency. 339
Coherently, in the present study, passing from rest to exercise implied a large 340 fall in LF and HF powers in control and under metoprolol. Conversely, under atropine 341 and double blockade, in which a suppression of the vagal modulation of HR was 342 obtained already at rest, no changes were found at exercise with respect to rest. 343
These results demonstrate that the well-known fall of HRV, which is usually observed 344 during exercise (37), is essentially a consequence of the withdrawal of the vagal our results suggest that vagal withdrawal is incomplete at the investigated powers, 347 because the LF and HF powers during exercise were still higher in control than with 348 atropine or double blockade, the two conditions in which a full blockade of muscarinic 349 receptors was attained. On the other hand, the fact that passing from rest to exercise 350 generated comparable results with metoprolol as in control, is coherent with the 351 reported decrease of the LF peak in humans (37, 39) . These data are in contrast with 352 the generally accepted notion that, during exercise, the degree of sympathetic 353 activation increases (46, 54) and the modulation of the heartbeat by the sympathetic 354 efferents becomes predominant (38, 45) . This may mean that HRV in exercise does 355 not reflect the degree of ongoing sympathetic activation. 356
When we look at the normalized variables at rest, none of the investigated 357 drugs could change the LF/HF significantly with respect to control: this reflects the 358 finding that the effects of drug administration on the LF and HF powers at rest were 359 of the same size. In contrast, during exercise, there was a tendency toward a lower 360 HF power than LF power. Yet this tendency, though not significant, was such as to 361 provide, at exercise compared to rest, significantly lower HFnu values in control and 362 under sympathetic blockade (only a tendency in A and in DB). Consequently, LF/HF 363 ratio resulted higher at exercise than at rest, at least in these two cases. 364
In the context of the present hypothesis, this would suggest that the 365 withdrawal of vagal tone at exercise onset might have had greater effects on the HF 366 than on the LF component of HRV. Alternatively, the relative increase of the LF 367 component of RR variability may suggest an increase of the cardiac sympathetic 368 modulation. Nevertheless, LFnu in double blockade was significantly lower and HFnu 369 significantly higher than in control, despite the lack of differences in the LF/HF ratio. 370
This may be due to the non-autonomic effect of an increase in ventilation that is 371 reflected on HRV through changes in venous return during exercise. A similar condition can be observed in a neurodegenerative disease such as the pure 373 autonomic failure. This condition is characterized by both a cardiac sympathetic and 374 parasympathetic denervation leading to PTOT values mimicking high dosage atropine 375 administration (16), in which a HF component of HRV, non-autonomic in origin, is 376 present (39). These apparently contradictory results prevent us from arriving at clear-377 cut conclusions concerning the mechanisms at the basis of relative powers in this 378 study. 379 380
Blood pressure variability 381
Arterial blood pressure at rest was unaffected by drug administration. The fact 382 that atropine did not act on systemic blood pressure, in agreement with previous 383 studies (15, 21) , is coherent with the notion that there is no cholinergic innervation in 384 most regional circulations. On the other hand, metoprolol is a selective blocker of 1-385 adrenergic receptors that are expressed specifically in the heart, not in arterioles, so 386 that it is not expected to induce changes in blood pressure. 387
Coherently, SAP variability was much less affected by atropine and double 388 blockade than HRV. According to Zhang et al. (61) , who investigated spontaneous 389 blood pressure variability under ganglionic blockade with Trimethaphan, the HF peak 390 of blood pressure variability is mediated by mechanical effects due to the breathing 391 cycle and cardiac filling: if this is so, one would not expect effects of any of the drugs 392 used in this study on the HF power for blood pressure. In fact, the changes in HF 393 power due to drug administration in the present study were much smaller than for 394 HRV, although significant under atropine and double blockade. Zhang et al. (61) also 395 attributed the LF power of blood pressure variability to either sympathetic activity or 396 intrinsic vascular rhythmicity: if this is so, no changes in LF were to be found with 397 atropine, metoprolol or double blockade: in fact, we found much smaller differences 398 in LF power due to drug administration for blood pressure variability than for HRV. 399
Yet these changes were consensual with those of HF power, being significant under 400 atropine and double blockade. These effects might have been an indirect 401 consequence of the role that the autonomic nervous system may play in modulating 402 the dynamic relationship between HRV and blood pressure variability (7, 61), with an 403 involvement of its parasympathetic branch. 404
Most remarkable are the differences observed when passing from rest to 405 exercise: the LF power for SAP increased in control, as expected (37, 39), and with 406 atropine, but not with metoprolol and in double blockade. This indicates that the 407 increase in LF power for SAP may be a consequence of increased sympathetic 408 modulation during exercise. No effects were observed under any drug on the HF 409 power: this means that the HF power of SAP is independent of the activity of the two 410 branches of the ANS. The lack of exercise effects on HF power under drug 411 stimulation explains why the PTOT did not differ significantly at exercise with respect 412
to rest under atropine. 413 DAP variability was unaffected by drug administration: this suggests that the 414 exercise effect on the LF power of SAP, related to a selective blockade of 1 415 adrenergic receptors, is mediated by a central (cardiac) rather than a peripheral 416 (arteriolar muscle vasodilation) action of the sympathetic branch of the ANS. 417 data support this hypothesis. Muscarinic receptors do not modulate smooth muscle 428 tone in most arterioles, including those of skeletal muscles. Thus, the 429 parasympathetic effect on arterial blood pressure variability indexes must be indirect. 430
Based on the present results, we speculate that baroreflexes may participate in the 431 modulation of the LF power of arterial blood pressure. The reduction of BRS 432 observed during exercise (51) support the idea of alfa-index changes as previously 433 reported (36). In the present study, the BRS reduction at exercise was observed only 434 in control and with metoprolol, but not with atropine and double blockade. This finding 435 reinforces the notion that withdrawal of vagal tone is responsible for the fall of BRS at 436 exercise onset (4, 34). Coherently, no differences in BRS among the four 437 investigated conditions were observed during exercise. 438
439
Study limitations 440
A limitation of this study may be suggested by the lack of differences between 441 control and metoprolol, as this may also suggest that the 1-adrenergic blockade 442 might have been incomplete. It is of note, however, that we used the same dose and 443 followed the same procedure of metoprolol administration as in a previous study (14) 444 in upright posture, which showed a significant resting HR decrease both in normoxia 445 and in acute hypoxia at rest as at exercise. Moreover, we observe that the 446 isoprenaline test provided unambiguous evidence of quasi-complete 1-adrenergic 447
blockade. 448
Another possible limiting factor is related to the fact that HR rate differed 449 remarkably among conditions. This may affect the HRV indexes in time domain per CONCLUSION 454
The results of this study support the tested hypothesis that vagal suppression 455 is responsible of the disappearance of the spontaneous HRV during exercise. The 456 observed effects on arterial blood pressure variability are indirectly related to the 457 action of the administered drugs, supporting the notion that blood pressure and HRV 458 are only partially-associated phenomena, possibly controlled by different 459 physiological mechanisms 460 and exercise (E) in the four experimental conditions: Control, Atropine, Metoprolol, and
Measured variables
Control
Metoprolol Atropine Double Blockade 
